Governor Josh Shapiro has revealed a significant investment of almost $3 million in Adare Pharma Solutions to support its headquarters’ relocation from New Jersey to Pennsylvania. Adare Pharma Solutions’ expansion plans, totaling $16.8 million, are expected to generate a minimum of 115 new job opportunities over the next three years while maintaining the current 200 positions in the state.
The Department of Community and Economic Development (DCED) has provided Adare with a significant funding package that includes a Pennsylvania Industrial Development Authority (PIDA) loan worth $2.4 million, a Pennsylvania First grant of $460,000, and a $100,000 workforce development grant for training.
Governor Shapiro expressed his competitive spirit and pride in Pennsylvania as the top state for innovative, growing, and successful companies. He expressed delight in Adare’s selection of Pennsylvania as its headquarters and growth destination over other states. The Governor highlighted Pennsylvania’s leadership in biotech and life sciences, emphasizing the talented workforce, access to key markets, and significant laboratory infrastructure. He believes that Adare’s growth in Pennsylvania will contribute to the state’s legacy while creating more opportunities for Pennsylvanians. The Governor affirmed that Pennsylvania is open for business and looks forward to welcoming more companies to the Commonwealth in the near future.
Rick Siger, the Secretary of DCED, has stressed the significance of the life sciences sector in Pennsylvania’s economic plan. Siger stated that the life sciences industry is one of the five essential sectors in the state’s Economic Development Strategy. He added that the state is committed to ensuring the sector’s continued growth and success in Pennsylvania. Siger expressed his delight in supporting Adare as they become another industry leader to establish their headquarters in the state. This announcement marks a significant milestone in the growth of the industry, and the state is thrilled to be a part of it.
Adare Pharma Solutions has announced the expansion of its manufacturing and packaging facilities in Philadelphia. The expansion includes two facilities – a 175,000-square-foot facility located at 7722 Dungan Road and a 128,000-square-foot facility at 1100 Orthodox Street. With the transfer of the company’s headquarters from New Jersey to the Dungan Road location, Adare Pharma Solutions is all set to increase its production capacity and scale up its operations.
A team of skilled economic development professionals, known as the Governor’s Action Team, spearheaded the project. Their main focus was to assist businesses in Pennsylvania that were considering relocation or expansion.
Adare Pharma Solutions CEO, Tom Sellig, is excited about the company’s relocation to Philadelphia. He expressed his enthusiasm by stating, “We are thrilled to announce the relocation of Adare’s global headquarters to Philadelphia. This decision highlights the remarkable efforts of Pennsylvania and Philadelphia in establishing themselves as crucial life sciences hubs for companies like ours. It is imperative for us to have access to a highly skilled talent pool and key markets, both of which are available in the Philadelphia area.”
Adare Pharmaceuticals is a contract development and manufacturing organization (CDMO) that operates globally and is driven by advanced technology. They are specialized in producing oral dosage forms for the pharmaceutical industry. The company has a remarkable track record of having developed and manufactured over 65 products that are sold globally. With seven facilities located in the United States and Europe, Adare is a leading name in the pharmaceutical industry.
Mayor Cherelle L. Parker emphasized the importance of Adare’s expansion, stating that the company’s decision to expand its two manufacturing and packaging facilities into Philadelphia headquarters is a testament to the city’s status as a global leader in innovative life sciences and biotechnology companies.
Parker expressed her pride in Adare’s growth, recognizing the company as a valuable asset not only to Philadelphia but to the Greater Philadelphia region as a whole.
